文献速递胸部肿瘤

ROS1阳性非小细胞肺癌常规临床实践中的特征与结局

Characteristics and Outcome of ROS1-Positive Non-Small Cell Lung Cancer Patients in Routine Clinical Practice.
PubMed 文献 · J Thorac Oncol · 2018-06-05

该回顾性研究分析了103例ROS1阳性NSCLC患者,中位年龄56岁,女性58.9%,从不吸烟者75.7%,腺癌98.1%。培美曲塞为基础化疗的ORR为53.3%,PFS 8.0个月;TKI治疗的ORR为70.7%,PFS 12.7个月。TKI治疗期间脑转移发生率(15.5%)高于化疗期间(6.7%)。

要点

  • ROS1阳性NSCLC多见于从不吸烟的腺癌患者,女性占58.9%。
  • TKI治疗ORR 70.7%,PFS 12.7个月;培美曲塞化疗ORR 53.3%,PFS 8.0个月。
  • TKI治疗期间脑转移发生率15.5%,高于化疗期间的6.7%。

核心结论

  • ROS1阳性NSCLC具有独特的临床特征,对TKI和培美曲塞为基础化疗均有效且持久。
  • 鉴于其独特特征和对常规化疗及TKI的不同反应,ROS1阳性NSCLC的治疗策略仍需进一步开发。

研究设计与样本

  • 回顾性分析103例连续ROS1阳性NSCLC病例,通过break-apart FISH(n=84)、NGS(n=23)或两者(n=3)鉴定。
  • 分析患者特征、脑转移发生率、化疗或TKI的应答等临床数据。

主要发现

  • 中位年龄56岁,女性58.9%,从不吸烟者75.7%,腺癌98.1%,多形性癌2例。
  • 最常见融合伴侣为CD74,其次为SDC4、EZR、TPM3、TFG、ZCCHC8、SLMAP和MYO5C,均保留ROS1酪氨酸激酶结构域。
  • 中位总生存期52.1个月(95%CI:23.6-未达到)。

关键数值与推荐

  • 90例接受培美曲塞为基础化疗:ORR 53.3%,PFS 8.0个月(95%CI:6.4-11.7)。
  • 50例接受TKI治疗:ORR 70.7%,PFS 12.7个月(95%CI:8.1-21.8)。
  • TKI治疗期间脑转移发生率15.5%,培美曲塞为基础化疗期间6.7%。

临床怎么用

  • ROS1阳性NSCLC患者可考虑TKI或培美曲塞为基础化疗,两者均显示有效。
  • TKI治疗期间需关注脑转移的发生,发生率高于化疗期间。

局限性

  • 回顾性研究设计。
  • 融合断点信息仅8例患者可用。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: ROS1-rearranged NSCLC is classified as a distinct molecular subset of NSCLC with a therapeutic target. ROS1 rearrangement is most often identified in never-smokers with adenocarcinoma and EGFR and ALK receptor tyrosine kinase gene (ALK) wild type. Treatment with tyrosine kinase inhibitors (TKIs), which target the ROS1 kinase domain, is considered the standard of care. TKIs have been shown to have a robust and durable response. However, information regarding the clinical outcomes of TKI treatment, including brain metastasis, remains limited. METHODS: We identified 103 consecutive cases of ROS1-positive NSCLC by using break-apart fluorescence in situ hybridization (n = 84), next-generation sequencing (n = 23), or both (n = 3). Information regarding fusion breakpoints was available for eight patients. Clinical data, including patient characteristics, incidence of brain metastasis, response to chemotherapy, or to TKIs, were retrospectively analyzed. RESULTS: The median patient age was 56 years, and 58.9% of the patients were female. Most of the patients (75.7%) were never-smokers. Adenocarcinoma was predominant (98.1%), and two cases with pleomorphic carcinoma were identified. Sixty percent of patients had an extrathoracic metastatic lesion, and 22% had an intracranial lesion at the initial presentation or at the time of recurrence. The median time to development of brain metastases was 12.0 months (range 2.1-84.1). The most common fusion partner was CD74 molecule gene (CD74), followed by syndecan 4 gene (SDC4), ezrin gene (EZR), tropomyosin 3 gene (TPM3), TRK-fused gene (TFG), zinc finger CCHC-type containing 8 gene (ZCCHC8), sacrolemma associated protein gene (SLMAP), and myosin VC gene (MYO5C). All of these fusion partners preserved the tyrosine kinase domain of ROS1. The median overall survival time was 52.1 months (95% confidence interval [CI]: 23.6-not reached). In the 90 patients who were treated with pemetrexed-based chemotherapy, the overall response rate and progression-free survival time were 53.3% and 8.0 months (95% CI: 6.4-11.7), respectively. The overall response rate and progression-free survival time were 70.7% and 12.7 months (95% CI: 8.1-21.8), respectively, for the 50 patients treated with TKIs. Brain metastasis was more often observed during TKI treatment (15.5%) than during pemetrexed-based chemotherapy (6.7%). CONCLUSIONS: ROS1-positive NSCLC has distinct clinical characteristics, with an effective and durable response to both TKIs and pemetrexed-based chemotherapies. Regardless, given its novel characteristics and distinct clinical responses to conventional chemotherapies and TKIs, the treatment strategy for ROS1-positive NSCLC remains to be further developed.

来源:J Thorac Oncol,查看原文。版权归原作者所有。

引用

  1. Park S, Ahn BC, Lim SW, et al. Characteristics and Outcome of ROS1-Positive Non-Small Cell Lung Cancer Patients in Routine Clinical Practice. J Thorac Oncol. 2018. PMID: 29883837. doi:10.1016/j.jtho.2018.05.026

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。